Is Royal Sense the Best Stock in Its Sector? A Look at the Numbers
- October 22, 2026
- Posted by: Kunal Singla
- Category: Market
Royal Sense CMP Rs 74.00 (22 Oct 2026). Market cap Rs 40 Cr. ROE 17.67%. P/E 5.53x versus Industry P/E 52.52x.
Quick Answer
Royal Sense is one of the names investors compare when screening the Medical Devices Trading sector. Whether it is the best stock in its sector depends on whether an investor prioritises return ratios, valuation or balance sheet strength. This article sets it against two named peers and the sector benchmark so you can judge for yourself.
Is Royal Sense the best stock in its sector? The stock trades on the BSE at Rs 74.00 as of 22 October 2026, within its 52-week range of Rs 67.50 to Rs 255.90. The sections below cover the business, the key ratios, a peer comparison and a closer look at valuation.
Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers
Click Here – Get Free Investment Predictions
About Royal Sense
Royal Sense Ltd trades in medical devices and pharmaceuticals, and company information says it was incorporated in 2023. Company information says it deals in advanced medical devices, pharmaceuticals and diagnostics and offers surgical solutions, supplying hospitals, laboratories, clinics and institutions with surgical accessories, instruments, equipment, consumables, reagents, diagnostic kits and disposable medical supplies. At a market capitalisation of Rs 40 Cr, it is tracked as part of the Medical Devices Trading sector on Univest.
Is Royal Sense the Best Stock in Its Sector?
Royal Sense makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, backed by its return on equity. Royal Sense’s 5.53x P/E is below the 52.52x Industry P/E, Thyrocare Technologies at 44.76x and Marksans Pharma at 27.32x, while its 17.67% ROE is lower than Thyrocare Technologies at 27.85%, though higher than Marksans Pharma at 13.82%, and its debt to equity ratio of 0.32 is above Thyrocare Technologies at 0.09 and Marksans Pharma at 0.11.
| Metric | Royal Sense |
|---|---|
| CMP (BSE) | Rs 74.00 |
| 52-Week High / Low | Rs 255.90 / Rs 67.50 |
| Market Cap | Rs 40 Cr |
| P/E (TTM) vs Industry P/E | 5.53x vs 52.52x |
| P/B | 1.04 |
| ROE | 17.67% |
| EPS (TTM) | Rs 13.37 |
| Dividend Yield | 0.00% |
| Debt to Equity | 0.32 |
Compare Royal Sense Against Other Medical Devices Trading Sector Stocks
How Royal Sense Compares Against Its Medical Devices Trading Sector Peers
The table below sets Royal Sense against 2 other Medical Devices Trading sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.
| Company | Market Cap (Rs Cr) | P/E | ROE | Debt to Equity |
|---|---|---|---|---|
| Royal Sense | 40 | 5.53 | 17.67% | 0.32 |
| Thyrocare Technologies | 7,873 | 44.76 | 27.85% | 0.09 |
| Marksans Pharma | 14,236 | 27.32 | 13.82% | 0.11 |
| Peer average (2 companies) | – | 36.04 | 20.84% | 0.10 |
Measured against the peer averages, Royal Sense’s P/E is 85 percent below the 36.04x average, and its ROE is 3.16 percentage points below the 20.84% average. An average of just two companies is a rough guide, so treat the gap as a pointer for further research and not as a verdict.
What Makes Royal Sense Worth Watching in Medical Devices Trading
- Scale: At Rs 40 Cr, its market capitalisation is smaller than Thyrocare Technologies (Rs 7,873 Cr) and Marksans Pharma (Rs 14,236 Cr), which is a useful reminder that the peers differ in size as well as in valuation.
- Sector drivers: Purchases by hospitals, laboratories and clinics, the range of products it can source and the margin it keeps between purchase and selling prices drive revenue and earnings.
- Key risk: A trading model usually carries thinner margins than a manufacturing one, and it depends on suppliers and a limited set of institutional buyers. Stock liquidity is also limited, so prices can move sharply on small volumes.
Royal Sense Valuation: Is It Justified?
At a P/B ratio of 1.04, the market pays about Rs 1.04 for every rupee of book value, and the EPS (TTM) of Rs 13.37 is the earnings base behind the P/E. The stock trades about 71 percent below its 52-week high and about 10 percent above its 52-week low. The company does not currently show a dividend yield, so returns for shareholders depend mainly on the share price. As with any single stock, investors should weigh these figures against their own valuation discipline and risk appetite rather than the sector label alone.
Also read – Is Oracle Financial Services Software the Best Stock in Its Sector? A Look at the Numbers
Download the Univest iOS App or Univest Android App to track Royal Sense and other Medical Devices Trading sector stocks.
How to Track Royal Sense Before You Invest
Before deciding whether Royal Sense deserves its label as the best stock in its sector for your own portfolio, compare it directly against Medical Devices Trading sector peers using the steps below.
- Open the Univest Screener and search for Royal Sense to view live price, valuation ratios, and peer comparisons within the Medical Devices Trading sector.
- Compare its P/E, P/B, and ROE against other Medical Devices Trading sector stocks before deciding if the current valuation fits your strategy.
- Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
- Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.
Conclusion
Royal Sense gives investors a clear set of numbers to work with, from returns and valuation to leverage and peer standing. Whether it earns the label of best stock in Medical Devices Trading depends on how much weight you give each of them and on how the business executes from here. Because the stock trades below its sector benchmark, the open question is whether earnings growth will close that gap or whether the discount is deserved. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Is Royal Sense the best stock in its sector?
Ans. There is no single definitive answer, because the best stock in a sector depends on whether an investor is prioritising returns, valuation or balance sheet strength. Royal Sense has a 17.67% ROE and trades at 5.53x P/E against a 52.52x Industry P/E. Against the 2 peers compared in this article, its ROE is below the 20.84% peer average and its P/E is below the 36.04x peer average. Its debt to equity ratio of 0.32 is above the 0.10 peer average, which matters because borrowing can inflate returns and add risk when business conditions weaken. These figures are best read together rather than in isolation, and they work as a starting point for your own research and not as a verdict.
What is the current share price of Royal Sense?
Ans. Royal Sense was trading at Rs 74.00 on the BSE as of 22 October 2026, and its 52-week range runs from Rs 67.50 to Rs 255.90. That leaves the share price 71 percent short of the 52-week high and 10 percent clear of the 52-week low. Its market capitalisation is Rs 40 Cr and its EPS (TTM) is Rs 13.37, which is the earnings figure behind the 5.53x P/E. Share prices change through the trading day, so check the live quote on Univest before acting on any number here.
What sector does Royal Sense belong to?
Ans. Royal Sense is classified under the Medical Devices Trading sector on Univest, and that group of listed companies is the reference point for the 52.52x Industry P/E used in this article. The 2 named peers compared here are Thyrocare Technologies and Marksans Pharma, chosen as comparable listed names so that the P/E, ROE and debt figures come from the same live data source. Investors who want a wider view can compare more Medical Devices Trading sector stocks on the Univest Screener, since no two companies in a sector have exactly the same business mix.
How does Royal Sense compare to its sector peers on P/E?
Ans. Royal Sense’s P/E of 5.53x is below the 36.04x average of the 2 named peers, with Thyrocare Technologies at 44.76x and Marksans Pharma at 27.32x. It also sits below the 52.52x Industry P/E, which is the benchmark for the wider Medical Devices Trading sector. A P/E that is below a peer average can reflect a valuation discount or premium, but it can also reflect different growth or return expectations, so it should be read alongside ROE and debt. Its P/B ratio of 1.04 gives one more view of how the market values its book value.
What is Royal Sense’s return on equity?
Ans. Royal Sense reported a return on equity of 17.67%, which is below the 20.84% average of its named peers, with Thyrocare Technologies at 27.85% and Marksans Pharma at 13.82%. ROE shows how much profit a company generates on every rupee of shareholders’ equity, so a higher figure generally points to more efficient use of capital. ROE is easier to trust when leverage is modest, and here the debt to equity ratio is 0.32 against a peer average of 0.10. It is worth checking whether the ROE has been stable over several years rather than relying on a single reading.
Should I invest in Royal Sense based on its sector position?
Ans. Sector position is only one input into an investment decision. Royal Sense has a 17.67% ROE and a 5.53x P/E, which make it worth researching further, and its dividend yield is 0.00%. You should also weigh its business outlook, earnings consistency, debt levels, your investment horizon and your own risk appetite before buying. Spreading money across several stocks and sectors reduces concentration risk, and this article is educational content, not investment advice. For personalised guidance, consult a SEBI-registered advisor.
